Navigation Links
Alopecia in Medical Technology

Is Your Hair Taking a Break?

... occurred in relation to the hair loss." alopecia Areata An autoimmune form of hair loss that can affect men and women, alopecia areata, occurs when the body's white blood cells ... unpredictable from person to person. For example, alopecia areata can happen overnight or occur gradually ...

Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth

... LaserComb in the treatment of Androgenetic alopecia in males commonly known as 'male pattern ... the treatment of certain classes of Androgenetic alopecia in males. The adverse event profile was ... treatment for hair loss caused by Androgenic alopecia in males." About the HairMax LaserComb ...

R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023

... is being developed by our company as a therapeutic drug of androgenetic alopecia (male pattern baldness; see the note below) has been completed. ... develop a drug that will become useful for the patients with androgenetic alopecia as soon as possible. Note: Androgenetic alopecia: Due to the ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... and rash (29% vs 12%) - In addition, 19% vs 52.3% reported alopecia (all grades) - Grade 3/4 hematologic ARs reported in >5% ... platelets/mm3, 61%), nausea (18%), asthenia (7%), fever (8%), alopecia (9%), vomiting (8%), diarrhea (5%), and stomatitis (5%) ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... and fluorouracil arm (PF) had grade 3/4 neutropenia (76.9% vs. 52.5%), alopecia (11.6% vs. 0%), anemia (9.2% vs. 12.8%) and infection (6.9% vs. 6.1%). ... vs 8%), and grade 3/4 neutropenia (83% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% vs. 3%) than those in the PF group. Patients ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...

AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne

... risks and allowing for the treatment of both males and females. In addition to acne indication, AndroScience is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar ...

RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial

... adverse events (greater than or equal to 10%) suspected of being related to study treatment were neutropenia, lymphopenia, stomatitis, leukopenia, alopecia and anemia. Study details: abstract #406 An open-label, multicenter Phase I trial evaluated daily RAD001 (2.5 mg, 5 mg and 10 mg) and ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of ...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

... events in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAR) and the Maintenance Phase (TEMODAR alone), respectively, were alopecia 69%, 55%; fatigue 54%, 61%; nausea 36%, 49%; vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; constipation 18%, 22%; with the following ...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include ...

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients

... headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 ...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

... are: flu-like symptoms, including headache, fatigue, aches and pains, fevers and chills; depression, nausea, loss of appetite and diarrhea; insomnia; alopecia (hair loss); a reaction at the site of injection; changes in blood liver function tests and in blood cell counts, including leukopenia (low white ...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

... and only one patient discontinued treatment for an adverse event. Noticeably absent were toxicities common to cytotoxic chemotherapy including alopecia and myelosuppression. The Injectable Suspension product provided considerable advantages over the Injection product, including shorter time of ...

GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)

... was maintained through repeat cycles.(2) The most commonly reported all-cause adverse events by patients receiving casopitant included neutropenia, alopecia and fatigue, and were generally balanced across treatment arms.(2) About Casopitant Casopitant is an NK-1 receptor antagonist in Phase III ...

PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C

... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...

Roche responds to announcement of 'IDEAL' hepatitis C trial results

... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...

Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients

... Non-hematologic adverse events included stomatitis (10/27 patients), skin rash (10/27), diarrhea (9/27), nausea (7/27), vomiting (5/27) and alopecia (2/27). The study has shown that CPX-351 is capable of inducing marrow aplasia with few severe non-hematologic adverse events. "CPX-351 is a ...

Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium

... safety profile is distinctly different from that of most cytotoxic agents. It does not cause myelosuppression (depression of the immune system) or alopecia (hair loss) like many currently available treatments for cancer. In phase 1/2 trials it has induced tumor regressions and/or caused disease ...

Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin

... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...

Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks

... in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), neutropenia (27%), nausea/vomiting (25%), rigors (25%), anorexia (24%), injection site reaction (23%), arthralgia (22%), depression (20%), ...

GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer

... The most common (>10%) non-hematologic adverse reactions (all grades) were nausea (27%), diarrhea (14%), vomiting (19%), fatigue (11%) and alopecia (10%).(2) About Small Cell Lung Cancer (SCLC)(3) SCLC is caused by an uncontrolled growth of cells beginning on the surface of the lung's breathing ...

Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery

... with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), and grade 3/4 neutropenia (84% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% vs. 3%) than those in the PF group. Patients in the PF group had more grade 3/4 thrombocytopenia (11% vs. 4%), stomatitis ...

Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment

... of patients with MBC were neutropenia (48%); alopecia (18%); leukopenia (11%); anemia (7%); fatigue ... (6%); creatinine elevation (5%); alopecia (1%-13%); and dyspnea (1%-7%). The most common ... events (all grades) were RBC transfusion (38%), alopecia (49%), neuropathy/sensory (29%), nausea (69%), ...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

... the CAELYX or the observation arm. The incidence of nausea/vomiting and alopecia were low and manageable; 21 percent of patients experienced grade 1 or 2 ... (a skin irritation, typically occurring on the hands and feet), rash, and alopecia (hair loss). About Schering-Plough Schering-Plough Corporation is a ...

Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C

... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2 percent of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include insomnia, ...

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting

... site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2 percent of patients receiving PEGINTRON. alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON. Psychiatric adverse events, which include insomnia, ...

Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer

... and, at a median follow-up of 14.9 months, the median time to progression was 8.7 months and the overall survival was 16.8 months Neurotoxicity and alopecia were minimal and there were no cases of hand–foot syndrome reported in this study. Study author, Dr. Hamid Y. Sheikh of the Christie Hospital ...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

... may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine ...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

... to 20% included: peripheral sensory neuropathy 60% (Grade 3/4: 14%); fatigue/asthenia 50% (Grade 3/4: 14%); myalgia/arthralgia 49% (Grade 3/4: 8%); alopecia 48% (Grade 3/4: 0%); nausea 42% (Grade 3/4: 2%); stomatitis/mucositis 29% (Grade 3/4: 7%); vomiting 29% (Grade 3/4: 1%); diarrhea 22% (Grade 3/4: ...

Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology

... through prior ifosfamide (IFOS) treatment. ZIO-201 was shown to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported. Based on this encouraging data, enrollment has been expanded to include additional patients. "Ifosfamide ...
Other Contents
(Date:7/24/2014)... smog-free Los Angeles, where electric cars ply silent freeways, ... heat from beneath the earth, from howling winds and ... study finds that it is technically and economically feasible ... by clean, renewable energy. Published in Energy , ... and reliable energy supply in California that could create ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
(Date:7/24/2014)... Iyer, O.D., a low vision specialist at The University ... School, has been awarded a grant to help Harris ... eyeglasses, medication or surgery. , Even with corrective lenses, ... best. However, there are a variety of low vision ... help offset their vision loss. , Iyer is using ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4The microbes make the sake brewery 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2
(Date:7/24/2014)... A few weeks have passed since ... high jump by Inika McPherson is a feat to ... USATF National Championships hosted the best track and field ... won US Nationals with the 2nd best jump in ... the biggest height over head jump in history. , ...
(Date:7/24/2014)... tumors, exposure to dim light at night made the ... to data published in Cancer Research , a ... negative effects of dim light exposure on tamoxifen treatment ... the night. , "Resistance to tamoxifen is a growing ... Steven M. Hill, PhD, professor of structural and cellular ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... online training course designed to help users generate traffic ... generating a buzz of excitement throughout the internet marketing ... the attention of HonestyFirstReviews.com’s Tiffany Hendricks prompting a comprehensive ... who’s been involved in internet marketing will tell you, ...
(Date:7/24/2014)... July 24, 2014 Ticket Down is ... Tickets in Denver at the Sports Authority Field on July ... World Football Challenge) has brought some of the best club teams ... the World Cup still being raved about weeks after its completion, ... to see some of the biggest stars in the world compete. ...
(Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
Breaking Medicine News(10 mins):Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Traffic And Leads Training Academy - Review Examining Jeff Johnson’s New IM Course Released 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4
Other TagsOther Tags